LaBarre Michael J.'s Form 4 filing
Halozyme Therapeutics, Inc. (HALO) · filed Feb 27, 2025
- Accession no.
- 0001415889-25-005899
- Filed
- Feb 27, 2025
- Trade date
- Feb 25-27, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.26M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| LaBarre Michael J.CIK 0001507174 | Officer (SVP, CHIEF TECHNICAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 25, 2025 | Common Stock | SSaleDisposed | −9,300 | $58.01 | −$539,493 | 186,153 | Direct | |
| Feb 25, 2025 | Common Stock | SSaleDisposed | −700 | $58.67 | −$41,069 | 185,453 | Direct | |
| Feb 26, 2025 | Common Stock | SSaleDisposed | −9,400 | $58.09 | −$546,046 | 176,053 | Direct | |
| Feb 26, 2025 | Common Stock | SSaleDisposed | −600 | $58.65 | −$35,190 | 175,453 | Direct | |
| Feb 27, 2025 | Common Stock | SSaleDisposed | −1,597 | $58.25 | −$93,025.25 | 173,856 | Direct | |
| Feb 27, 2025 | Common Stock | SSaleDisposed | −100 | $58.74 | −$5,874 | 173,756 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.